Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

AbbVie

Bristol-Myers

Pfizer

Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) Chairman Warren Buffett has invested in four large drugmakers as the world faces yet another wave of the raging COVID-19 pandemic. What Happened: Regulatory filings made with the United States Securities and Exchange Commission reveal that the legendary investor picked up shares worth nearly $136 million in drugmaker Pfizer Inc (NYSE: PFE) in the latest quarter.

Warren Buffett's Berkshire Bets On These Four Drugmakers Amid Pandemic

The Oracle of Omaha and his team opened new positions in the underperforming sector.

Warren Buffett Bought 4 Pharma Giants in Q3

Snowflake

T-Mobile US

Warren Buffett (Trades, Portfolio)'s $545.8 billion conglomerate, Berkshire Hathaway Inc. (NYSE:BRK.A)(NYSE:BRK.B), disclosed its equity portfolio for the third quarter of 2020 on Monday.

Warren Buffett Buys 6 Stocks in 3rd Quarter, Dumps Costco

Warren Buffett's Berkshire Hathaway is making a big bet on the health care sector at a time when the Covid-19 pandemic continues to be a major crisis in the United States.

Warren Buffett's Berkshire Hathaway makes big bets on drug stocks

Warren Buffett's Berkshire Hathaway invested in AbbVie, Bristol-Myers Squibb, Merck, and Pfizer in the third quarter. The billionaire investor's company disclosed the new holdings in a regulatory filing on Monday. Berkshire boasted stakes worth more than $1.8 billion in each of AbbVie, Bristol Myers Squibb, and Merck as of September 30. It also owned $136 million of Pfizer stock. Buffett and his team also trimmed their Apple stake, which is easily the most valuable holding in their stock portfolio. Visit Business Insider's homepage for more stories. Warren Buffett's Berkshire Hathaway plowed billions of dollars into Pfizer, Merck, and other pharmaceutical stocks in the third quarter, a regulatory filing revealed on Monday.

Warren Buffett's Berkshire Hathaway reveals stakes in AbbVie, Merck, Pfizer, and other 'big pharma' stocks

Warren Buffett's Berkshire Hathaway Inc said on Monday it has begun investing in four large drugmakers.

Buffett's Berkshire invests in several big drugmakers

The FDA approves Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer. This marks the first nod for Keytruda in the breast cancer setting.

Merck's (MRK) Keytruda Gets FDA Nod for Severe Breast Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1

BeiGene

BioNTech SE

Calliditas Therapeutics AB

I-Mab

Thermo Fisher Scientific

Innoforce, a Hangzhou company, formed a JV with Thermo Fisher Scientific to build a large biologics and steriles drug development and manufacturing facility in the Hangzhou Airport Economic Demonstration Area. Decheng Capital had good reason to be pleased when Merck paid $2.75 billion to acquire VelosBio, a company formed in 2017 to develop ROR1 ADCs for cancer.

Week In Review: RemeGen, A Yantai Biologics Company, Completes $515 Million Hong Kong IPO

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Approves KEYTRUDA Plus Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 (CPS ≥10)

FDA Approves Merck's KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Patients With Locally Recurrent Unresectable or Metastatic Triple‑Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10)

MERCK Kommanditgesellschaft auf Aktien's (MKGAF) Management on Q3 2020 Results - Earnings Call Transcript

Comcast

CVS Health

Fiserv

Johnson & Johnson

Mondelez

Investors have been waiting for value stocks to catch up to growth stocks for a decade now, and some think they're seeing signs of the long-awaited rotation from pricey stocks to cheap ones. Value stocks had a heady few days in the second week of November when they trounced some of the biggest growth names in the market.

7 Best Value Stocks for the 'Great Rotation'

Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.

Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study

KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA Demonstrated Statistically Significant Improvement Versus Sunitinib as First-Line Treatment for Patients With Advanced RCC

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Statistically Significant Improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Versus Sunitinib as First-Line Treatment for Patients…

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients

Merck Announces KEYNOTE-598 Trial Evaluating KEYTRUDA® (pembrolizumab) in Combination With Ipilimumab Versus KEYTRUDA Monotherapy in Certain Patients With Metastatic Non-Small Cell Lung Cancer To Stop for Futility and Patients to Discontinue.

Citigroup

GlaxoSmithKline

Seaboard

Kahn Brothers (Trades, Portfolio) has released its third-quarter portfolio. Throughout the portfolio holdings were reduced or sold completely, with the largest changes coming from Merck & Co. Inc. (NYSE:MRK), Bristol-Myers Squibb Company (NYSE:BMY), GlaxoSmithKline PLC (NYSE:GSK), Citigroup Inc. (NYSE:C) and Seaboard Corp. (SEB).

Kahn Brothers' Biggest 3rd-Quarter Sells

Merck (NYSE: MRK) — known as MSD outside the US and Canada — announced recently that it entered into a definitive agreement pursuant to which Merck (through a subsidiary) will buy all of the outstanding shares of VelosBio for $2.75 billion in cash. The post Why Merck (MRK) Is Buying VelosBio For $2.75 Billion In Cash appeared first on Pulse 2.0.

Why Merck (MRK) Is Buying VelosBio For $2.75 Billion In Cash

Merck's stock lost more than 28% – dropping from $92 at the beginning of the year to $66 in late March – then jumped 21% to around $80 now. That means it has partially recovered to the levels where it started the year.

Merck Stock Poised For 25% Gains

The cancer-focused pharmaceutical giant will buy a privately held biotech developing a potential first-in-class treatment.

Merck Makes a $2.8 Billion Bet on an Experimental New Cancer Drug

Merck early Thursday announced a $2.75 billion agreement to buy privately held VelosBio, a maker of promising drugs to treat lung, breast, lymphoma and other types of cancer; MRK stock rose. The post Merck Expands Cancer Drug Portfolio With $2.75 Billion Acquisition appeared first on Investor's Business Daily.

Merck Expands Cancer Drug Portfolio With $2.75 Billion Acquisition

Amgen

Discovery

eBay

Macerich

Simon Property Group

Our call of the day offers up several stocks that busy, distracted investors have been overlooking. Smead Capital Management's CIO says they are stocks to hold for the long run.

Need to Know: These 7 unloved stocks are for the long haul, says contrarian manager

RESEARCH TRIANGLE PARK, N.C., Nov. 5, 2020 /PRNewswire/ -- Pappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. ("VelosBio" or the "Company"), has entered into a definitive agreement to be acquired by...

Pappas Capital Portfolio Company VelosBio to be Acquired by Merck

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

LYNPARZA® (olaparib) in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA12-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

LYNPARZA® (olaparib) Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shares of Merck & Co. Inc. rose 1.0% in premarket trading Thursday, after the drug maker announced a deal to buy privately held biopharmaceutical company VelosBio Inc. for $2.75 billion in cash. The deal is expected to close by the end of 2020.

News for Merck Stock (MRK)